The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.

Macaluso, Fabio Salvatore

The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. [electronic resource] - Inflammatory bowel diseases 01 2021 - 182-189 p. digital

Publication Type: Journal Article; Multicenter Study; Observational Study

1536-4844

10.1093/ibd/izaa036 doi


Biosimilar Pharmaceuticals--therapeutic use
Gastrointestinal Agents--therapeutic use
Humans
Inflammatory Bowel Diseases--drug therapy
Infliximab--therapeutic use
Prospective Studies
Treatment Outcome